The Listeria monocytogenes σB Regulon and Its Virulence-Associated Functions Are Inhibited by a Small Molecule by Palmer, M. Elizabeth et al.
The Listeria monocytogenes B Regulon and Its Virulence-Associated
Functions Are Inhibited by a Small Molecule
M. Elizabeth Palmer,a Soraya Chaturongakul,a,b Martin Wiedmann,a and Kathryn J. Boora
Department of Food Science, Cornell University, Ithaca, New York, USA,a and Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailandb
ABSTRACT Thestress-responsivealternativesigmafactor BisconservedacrossdiverseGram-positivebacterialgenera.In Liste-
ria monocytogenes, B regulates transcription of >150 genes, including genes contributing to virulence and to bacterial survival
underhost-associatedstressconditions,suchasthoseencounteredinthehumangastrointestinallumen.Aninhibitorof
L. monocytogenes B activity was identiﬁed by screening ~57,000 natural and synthesized small molecules using a high-
throughputcell-basedassay.Thecompoundﬂuoro-phenyl-styrene-sulfonamide(FPSS)(IC503.5M)downregulatedthema-
jority of genes previously identiﬁed as members of the B regulon in L. monocytogenes 10403S, thus generating a transcriptional
proﬁlecomparabletothatofa10403S sigBstrain.Speciﬁcally,ofthe208genesdownregulatedbyFPSS,75%hadbeenidenti-
ﬁedpreviouslyaspositivelyregulatedby B.Downregulatedgenesincludedkeyvirulenceandstressresponsegenes,suchas
inlA, inlB, bsh, hfq, opuC, and bilE. From a functional perspective, FPSS also inhibited L. monocytogenes invasion of human in-
testinal epithelial cells and bile salt hydrolase activity. The ability of FPSS to inhibit B activity in both L. monocytogenes and
Bacillus subtilis indicates its utility as a speciﬁc inhibitor of B across multiple Gram-positive genera.
IMPORTANCE TheBtranscriptionfactorregulatesexpressionofgenesresponsibleforbacterialsurvivalunderchangingenvi-
ronmental conditions and for virulence; therefore, this alternative sigma factor is important for transmission of L. monocyto-
genesandotherGram-positivebacteria.Regulationof Bactivityiscomplexandtightlycontrolled,reﬂectingthekeyroleofthis
factorinbacterialmetabolism.Wepresentmultiplelinesofevidenceindicatingthatﬂuoro-phenyl-styrene-sulfonamide(FPSS)
speciﬁcally inhibits activity of B across Gram-positive bacterial genera, i.e., in both Listeria monocytogenes and Bacillus subti-
lis.Therefore,FPSSisanimportantnewtoolthatwillenablenovelapproachesforexploringcomplexregulatorynetworksin
L. monocytogenes and other Gram-positive pathogens and for investigating small-molecule applications for controlling patho-
gentransmission.
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L
isteria monocytogenes causes a rare but potentially fatal food-
borne disease called listeriosis. With its high fatality rate, liste-
riosisaccountsfor~10%ofalldeathsfromfood-bornediseasesin
the United States (1). L. monocytogenes can transition from a sap-
rotrophic existence under a wide range of environmental condi-
tions (2) to intracellular infection in a diverse array of hosts (3).
The ability of L. monocytogenes to transform from saprotroph to
intracellular pathogen is inﬂuenced by regulatory networks that
enablebacterialsurvivalandcontrolvirulencefactorexpressionin
response to environmental signals (4).
Sigma B is one important component of a network that links
environmental stress survival and virulence in L. monocytogenes
(5, 6). Sigma factors are dissociable subunits of prokaryotic RNA
polymerase. The association of a speciﬁc alternative sigma factor,
e.g., B, with core RNA polymerase under appropriate environ-
mental conditions enables the rapid redirection of regulon tran-
scription in response to environmental signals. More than 150
genes comprise the L. monocytogenes B regulon (7, 8).
B networks, including its interactions with PrfA, inﬂuence
transmission of L. monocytogenes during both the gastrointestinal
(9) and systemic stages of infection (5, 10). Complex interactions
occur between B and PrfA-dependent gene regulation (5, 10);
PrfA is the master regulator of L. monocytogenes virulence gene
expression. B directly regulates prfA transcription via the P2prfA
promoter (11–13) and also indirectly regulates PrfA activity. Spe-
ciﬁcally, B downregulates PrfA activity in intracellular L. mono-
cytogenes, thus moderating expression of PrfA-dependent viru-
lence genes and thereby reducing host cell damage incurred by
these virulence gene products (5).
Ageneralstrategyforexploringcomplexbiologicalnetworksis
to disrupt a targeted element of that network and then examine
the consequences. High-throughput screening of small-molecule
libraries has been used effectively to identify agents that disrupt
speciﬁc bacterial targets, including an inhibitor of the virulence
regulator ToxT in Vibrio cholerae (14). We screened multiple
small-molecule libraries to identify an inhibitor of the stress re-
sponse and virulence-associated regulator B. The most promis-
ingsmallmoleculewasfurtherassessedusinganL.monocytogenes
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PCR (qRT-PCR) of B-dependent genes, and phenotypic proﬁl-
ing, including Caco-2 cell invasion assays and qualitative assess-
ment of bile salt hydrolase activity. The compound also was
evaluated for its ability to inhibit B activity in B. subtilis.
RESULTS
Ahigh-throughputcell-basedscreenidentiﬁespromisingsmall
molecules that interfere with B activity. A high-throughput
cell-basedscreeningassay(HTS)wasusedtoidentifycompounds
thatinhibitexpressionoftheB-dependentopuCApromoter(15)
without affecting L. monocytogenes growth (Chembank Screening
Project:SigBInhibition).Basedontheprimaryscreen,41putative
inhibitors of B activity were selected for secondary cell-based
screening(Fig.S1).CompoundsthatinducedBactivitywerenot
analyzed further.
IC50 values, i.e., compound concentrations needed to inhibit
50% of B activity, were determined from secondary screening
results for each of the 41 compounds. For 14 compounds, B
activitywasinhibitedataconcentrationlowerthanthatusedin
the primary screen; however, 11 compounds were eliminated
from further consideration based on mammalian cell cytotox-
icitydatainChemBank(http://chembank.broad.harvard.edu).
The three remaining L. monocytogenes B inhibitors were
4-hydrazino[1]benzofuro[3,2-d]pyrimidine; 3-(cyclohexyla-
cetyl)-4-hydroxy-2H-chromen-2-one; and (E)-N,2-
diphenylethenesulfonamide. Among these, the most effective
B activity inhibitor, (E)-N,2-diphenylethenesulfonamide
(IC50  ~15 M), which was a member of the ChemDiv3 library
(Table S1), was not commercially available. Therefore, ﬂuoro-
phenyl-styrene-sulfonamide (FPSS), an analog of the original
compound, was obtained for further study. Relative to (E)-N,2-
diphenylethenesulfonamide, FPSS has ﬂuorine substituted for a
hydrogen (Fig. 1). Based on quantitative reverse transcriptase
PCR (qRT-PCR) results, FPSS was the most effective B inhibitor
among the three compounds. Data available in ChemBank indi-
cated minimal evidence and no evidence of mammalian cell cyto-
toxicity for (E)-N,2-diphenylethenesulfonamide and FPSS, re-
spectively.
We hypothesized that a small molecule that directly binds B
might also prevent B from associating with core polymerase,
thereby inhibiting B activity. Therefore, the ability of various
small molecules to bind B was assessed using a small-molecule
(SMM) screen with His-tagged B (Fig. S2; Table S1). Of three
putative ligands—i.e., 3-amino-4-oxo-N-(pyridin-3-ylmethyl)-
3,4-dihydroquinazoline-2-carboxamide [Maybridge], ethyl
1-benzyl-5-[3-(tert-butylamino)-2-hydroxypropoxy]-2-methyl-
1H-indole-3-carboxylate [Chemical Diversity], and 5-phenyl-
4,7-dihydrotetrazolo[1,5-a]pyrimidine [Maybridge])—none in-
hibited B activity in the bile salt hydrolase activity assay, and
therefore, none were evaluated further.
Multiple lines of evidence support B activity inhibition by
FPSS. Quantitative qRT-PCR assessment of the effects of FPSS
concentrations from 1 Mt o6 4Mo nB-dependent transcrip-
tion showed that exposure to 64 M FPSS resulted in a ~40-fold
reductionintranscriptlevelsforbothB-dependentgenesopuCA
and gadA relative to their transcript levels in cells not treated with
FPSS (Fig. 2) (P  0.05, GLM [general linear model] with post-
hoc Tukey’s honestly signiﬁcant difference [HSD] test). opuCA
andgadAtranscriptlevelsincellstreatedwithFPSS(rangingfrom
8Mto64M)werenotsigniﬁcantlydifferentfromthoseinthe
sigB strain (P  0.05). At 4 M, FPSS signiﬁcantly reduced
opuCA and gadA transcript levels compared to those in 10403S
withoutFPSS(P0.05)butnottolevelsequivalenttothoseinthe
sigB strain (Fig. 2). The FPSS concentration yielding half the
maximal inhibition (IC50) was calculated as 3.5 M for opuCA
and 3.0 M for gadA. Importantly, absolute transcript levels for
the housekeeping genes rpoB and gap were not different in
L. monocytogenes with and without exposure to FPSS, indicating
that FPSS speciﬁcally inhibits transcription of B-dependent
genes without affecting transcription of housekeeping genes.
The phenotypic effects of various concentrations of FPSS on
theactivityofbilesalthydrolase,theproductoftheB-dependent
gene bsh, which is required for L. monocytogenes survival in vivo
(6), were qualitatively assessed. L. monocytogenes treated with
96 M and 193 M FPSS showed no bile salt hydrolase (BSH)
activity, with no apparent effect on the ability of L. monocytogenes
to grow on brain heart infusion (BHI) agar. When treated with
290MFPSS,L.monocytogenesproducednoBSHactivitybutalso
grew poorly on BHI (data not shown).
L. monocytogenes whole genome microarray identiﬁed 208
genes downregulated by treatment with FPSS. Transcriptional
consequences of FPSS treatment were proﬁled using an L. mono-
cytogenes whole-genome microarray. FPSS treatment downregu-
lated transcript levels for 208 genes and upregulated transcript
levelsfor32genes(adjustedPvalueof0.05andanabsolutefold
change [FC] value of 2). In previous studies with L. monocyto-
genes 10403S and EGD-e, 281 genes were identiﬁed as positively
regulated by B under at least one assay condition, and 137 genes
aspositivelyregulatedbyBundertwoormoreofthesevenassay
conditions examined (5–8, 16, 17) (Table S2). Overall, FPSS sig-
niﬁcantlyreducedtranscriptlevelsof56%(156/281)ofgenespre-
viously identiﬁed as being upregulated by B in at least one study
and of 91% (125/137) of genes identiﬁed as being upregulated
by B in two or more studies (Table 1; Table S3). Of the 208
FPSS-downregulated genes, 115 were reported to be positively
regulated by B in both 10403S and EGD-e (5–8, 16, 17), with an
additional 21 genes reported to be positively regulated by B in
10403S (5, 7, 8, 17) and 20 reported to be positively regulated by
B in EGD-e (6, 16). FPSS downregulated transcript levels for
90% of genes with previously reported hidden Markov model-
identiﬁed B-dependent promoters (17). A number of operons
previously identiﬁed as being positively regulated by B (8) were
also signiﬁcantly downregulated after treatment with FPSS, in-
cludinginlAB,whichmediatesentryintononprofessionalphago-
cytes(18),andopuCABCD,whichisinvolvedincompatiblesolute
transport. The autoregulated sigB operon (7, 8, 19), consisting of
FIG 1 Chemical structure of the B activity inhibitor FPSS (ﬂuoro-phenyl-
styrene-sulfonamide). FPSS is a derivative of (E)-N,2-diphenylethene-
sulfonamide, the compound originally identiﬁed by HTS as the most effective
inhibitor of B activity. Relative to the structure of (E)-N,2-
diphenylethenesulfonamide, FPSS has a ﬂuorine substituted for a hydrogen.
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regulated by FPSS.
To evaluate FPSS effects on the function of other alternative
sigmafactors,transcriptlevelsforgenesintheHandLregulons
were assessed. Among the 30 genes previously identiﬁed as H
dependent (with an FC  2.0), 14 were signiﬁcantly downregu-
latedbyFPSS(adjustedP0.05,foldchange2);however,12
of those 14 genes are also B dependent. Gene set enrichment
analysis (GSEA) showed that the H-only regulon (i.e., genes that
are regulated only by H and not coregulated by B) was not
signiﬁcantly enriched among the genes differentially transcribed
as a result of FPSS treatment (false discovery rate [FDR] q 
0.472).GSEAalsoshowedthattheLregulonwasnotsigniﬁcantly
enriched as a result of treatment with FPSS (FDR q  0.836).
GSEA was used to determine if genes from speciﬁc biological
role categories were overrepresented among those differentially
affected by FPSS. Consistent with B’s role in bacterial stress re-
sponse, gene sets enriched among FPSS-downregulated genes in-
cluded those classiﬁed as (i) “Cellular Processes: Adaptations to
AtypicalConditions”and(ii)“EnergyMetabolism(other)”(FDR
q  0.060 and q  0.201, respectively). Previously identiﬁed B-
regulated genes also were signiﬁcantly enriched among FPSS-
downregulated genes (FDR q  0.0001). Gene sets enriched
among FPSS-upregulated genes included those classiﬁed as (i)
“Cellular Processes: Chemotaxis and Motility,” (ii) “Protein Fate:
ProteinFoldingandStabilization,”and(iii)“AminoAcidBiosyn-
thesis: Histidine Family” (FDR q  0.0001, q  0.008, and q 
0.031, respectively).
FIG 2 FPSS treatment reduces transcript levels of B-dependent opuCA and gadA. Normalized log-transformed opuCA (A) and gadA (B) transcript levels in
L.monocytogenes10403Sexposedto0.3MNaCltoinduceBactivityinthepresenceofFPSSatconcentrationsrangingfrom1to64M;controlsincludedstrains
10403SanditsisogenicsigBmutantexposedto0.3MNaCl.TranscriptlevelswerequantiﬁedbyqRT-PCR,log10transformed,andnormalizedtothegeometric
mean of the transcript levels for the housekeeping genes rpoB and gap. The data are means from three replicates; error bars show the standard deviations.
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ulated by B during infection in the murine intestine (6), includ-
ing 17 genes that had been identiﬁed as B dependent only in the
intestinalenvironment(TableS2).Amongthese17genes,9genes
were of unknown or hypothetical function. Several FPSS-
downregulated genes are recognized as contributing to virulence
and host infection (i.e., inlA, inlB inlD, bilEAB, bsh, hfq, clpC,
opuC, and gadA). Further, the PrfA regulon (i.e., genes regulated
bythepleiotropicvirulencegeneregulatorPrfA)wassigniﬁcantly
enriched among the genes downregulated by FPSS (FDR q 
0.095). Interestingly, 19 genes that were previously classiﬁed as
coregulated by PrfA and B (10, 20) were both upregulated in the
mouse spleen (10) and downregulated by FPSS, further support-
ing their B-dependent transcription. Among these 19 genes,
three were identiﬁed as potential virulence factors in murine and
tissue culture models (10, 22), including lmo1601 (encoding a
general stress protein), lmo1602 (encoding an unknown protein),
andlmo2157(encodingSepA,ametalloproteaseinStaphylococcus
epidermidis [21]), which is upregulated in L. monocytogenes dur-
ingintracellularinfection(22).FPSSalsodownregulatedlmo0937,
a PrfA-regulated gene that is upregulated in the mouse spleen at
48hpostinfection(10),andlmo0915,whichencodesacomponent
of a phosphotransferase system identiﬁed as a potential virulence
factor by Camejo et al. (10); neither gene had been identiﬁed pre-
viously as B dependent. Other B-dependent genes downregu-
lated by FPSS and upregulated during intracellular infection (22)
includelmo0232(clpC);lmo0445,whichencodesatranscriptional
regulator;lmo2672,whichencodesaproteinsimilartoatranscrip-
tional regulator; and lmo0783, which is a member of an operon
encoding mannose phosphotransferase system components.
FPSS-treated cells had lower transcript levels for a number of
genes that encode cell wall-associated proteins previously shown
to be upregulated under intracellular conditions (22) and in the
murine intestine (6); these genes include inlA, inlD, lmo0610,
lmo0880, and lmo2085, which all encode proteins with an LPXTG
sorting motif for cell wall anchoring, and inlB, which encodes a
protein with a GW domain that is important for binding host
ligands (23).
Three genes important for glycerol utilization (i.e., lmo1538,
lmo1539,andlmo1293)werealsodownregulatedbyFPSS;utiliza-
tion of glycerol as a carbon source in intracellular environments
(22)isrequiredforintracellularsurvival(24).Whilelmo1538(en-
codingaglycerolkinase)andlmo1539(encodingaglyceroluptake
facilitator) were downregulated by FPSS, they were previously re-
ported to be negatively regulated by B in stationary phase and
undersaltstressconditions(8).Interestingly,however,bothgenes
were upregulated by B in the intestine (6) and during intracellu-
lar replication (22). lmo1293 (glpD), which encodes a glycerol-3-
phosphate dehydrogenase, was previously reported to be posi-
tivelyregulatedbyBinL.monocytogenesexposedtosaltstress(8)
or grown intracellularly (24) and in the gastrointestinal tract (6)
but was downregulated by B in stationary-phase cells (8). Taken
together,ourdataprovideadditionalevidencesupportingthehy-
pothesis that the composition of the B regulon is dynamically
dependent on environmental conditions (7). Importantly, our
data also demonstrate that a number of genes downregulated by
FPSS are speciﬁcally regulated by B in the gastrointestinal envi-
ronment. For example, three additional genes downregulated by
FPSS (i.e., lmo0642, lmo1251, and lmo1930) had higher transcript
levelsintheL.monocytogenesparentstrainthaninthesigBstrain
whenbothweregrowninthemurineintestine(6),butthesegenes
didnotappeartobeBdependentunderotherinvitroconditions
(5, 7, 8, 16, 17)
OnlyasmallnumberofgenesupregulatedbyFPSShavebeen
identiﬁed previously as negatively regulated by B. Overall, 32
genes were identiﬁed with signiﬁcantly higher transcript levels in
FPSS-treated L. monocytogenes than in untreated cells (Table 1),
suggesting negative regulation of these genes by B. While 264
genes were previously identiﬁed as negatively regulated by B un-
der at least one condition (5–8, 16, 17), only 7 of the 32 FPSS-
upregulated genes were represented among these 264 genes. Fur-
ther, only 14 genes were previously identiﬁed as negatively
regulatedbyBunderatleasttwoenvironmentalconditions(5–8,
16, 17) and none of the 32 FPSS-upregulated genes were repre-
sented among these 14 genes. Very few genes appear to be consis-
tently repressed by B under various conditions, likely because
these genes are indirectly rather than directly regulated by B. Six
of the 7 FPSS-upregulated genes previously identiﬁed as nega-
tively regulated by B encode proteins with known functions, in-
cluding an ABC transporter (lmo2114), a posttranslocation chap-
erone (prsA), a methyl-accepting chemotaxis protein (lmo1699
and lmo1700), NADP glutamate dehydrogenase (lmo0560), and a
D-alanine-activating enzyme (dltA). While dltA (the ﬁrst gene in
an operon encoding proteins that modify lipoteichoic and wall
teichoicacids)waspreviouslyshowntobenegativelyregulatedby
B, other genes in this operon (i.e., lmo0973 [dltB] and lmo0971
[dltD])notpreviouslyidentiﬁedasBdependentwerealsosignif-
icantlyupregulatedfollowingFPSStreatment,suggestingthatthis
entire operon is negatively regulated by B, at least under some
conditions. Two genes, lmo2568 (unknown function) and
TABLE 1 Relationships between genes identiﬁed as differentially
expressed after treatment with FPSS and genes identiﬁed previously as
B dependent
Gene type
No. of genes (no. with an upstream
B-dependent promotera)
Downregulated
by FPSS
Upregulated
by FPSS
Identiﬁed previously
as positively regulated by Bb
152 (86) 2 (0)
Identiﬁed previously
as negatively regulated by Bc
2 (0) 7 (0)
Reported previously
to be positively or negatively
regulated under different conditions
or in different studiesd
4 (0) 0
Having no previous evidence
of B-dependent transcript levels
50 (0) 23 (0)
Total 208 (86) 32 (0)
a Genes were classiﬁed with upstream B-dependent promoters by in silico analysis
using a hidden Markov model as described by Oliver et al. (17).
b Genes were classiﬁed as positively regulated by B based on evidence from at least one
of six previous microarray or RNA-Seq studies (5–8, 16, 17) (see Tables S2 and S3 for
details).
c Genes were classiﬁed as negatively regulated by B based on evidence from at least
one of six previous microarray or RNA-Seq studies (5–8, 16, 17) (see Tables S2 and S4
for details).
d Genes reported as differentially regulated in previous microarray or RNA-Seq studies
(5–8, 16, 17), including genes reported as negatively regulated by B in one study and
positively regulated by B in another study and genes that were found to be negatively
and positively regulated by B under different conditions in the same study (see
Table S2).
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were upregulated by FPSS but had previously been reported to be
positively regulated by B in the intestine (6) and during various
growth phases (16), respectively. Among the genes not previously
reported as B dependent that were upregulated by FPSS, some
were involved in ABC transport, motility, and cell division, but
most had unknown functions (Table S4).
FurthersupportingtheideathatFPSStreatmentofL.monocy-
togenesgeneratestheequivalentofasigBphenotype,GSEAiden-
tiﬁed genes in the “motility and chemotaxis” role category as en-
riched among genes upregulated by FPSS (FDR q  0.0001),
consistent with previous reports that B negatively regulates
motility-related functions (8). In addition, six FPSS-upregulated
genes(lmo0678tolmo0681,lmo0685,andlmo0686)notdescribed
previously as negatively regulated by B were located in a large
ﬂagellar biosynthesis and motility operon (lmo0673 to lmo0718)
containing 13 genes recognized as negatively regulated by B(8).
Astranscriptionofanumberofmotilityrelatedgeneswasaffected
by FPSS, GSEA was also performed on the regulons of the known
chemotaxis- and motility-related regulators DegU, MogR, and
CodY. The DegU operon, as deﬁned by Williams et al. (25), was
enriched among FPSS-upregulated genes (FDR q  0.0001);
DegU is an activator of ﬂagellum biosynthesis (26). Speciﬁc
DegU-regulated genes identiﬁed among the FPSS-upregulated
genes include six genes in the ﬂagellum biosynthesis operon
(lmo0673 to lmo0718) as well as the B-repressed (8) methyl-
accepting chemotaxis operon (lmo1699 and lmo1700) (25). The
CodY regulon was also signiﬁcantly enriched among FPSS-
upregulatedgenes(FDRq0.0001);CodYisanegativeregulator
of genes encoding ﬂagellar components in L. monocytogenes (27).
Although MogR, the transcriptional repressor of ﬂagellum genes
(28,29),wasshownpreviouslytobeBdependent(6),itsregulon
(29) was not signiﬁcantly enriched among the genes differentially
regulated by FPSS (FDR q  0.257).
FPSS reduces L. monocytogenes invasion of human entero-
cytes.FPSStreatment(ateither8Mor64M)reducedL.mono-
cytogenes’ ability to invade Caco-2 human enterocytes by 1.50 log
( 0.49) and 1.42 log ( 0.39), respectively, compared to the
untreated control bacteria (Fig. S3) (P  0.05). Invasion of
L. monocytogenes treated with 8 M FPSS was not signiﬁcantly
different from invasion by the sigB strain, which also showed
signiﬁcantly reduced invasion compared to the untreated parent
strain (P  0.05), providing phenotypic evidence of FPSS inhibi-
tion of B-regulated virulence functions that contribute to orally
acquired listeriosis (9).
FPSS inhibits B activity in B. subtilis, indicating effective-
ness across genera. To determine if FPSS affects B activity in
bacteria other than L. monocytogenes, the compound was tested
for its ability to speciﬁcally inhibit B activity in B. subtilis. FPSS
(64 M) signiﬁcantly inhibited B-dependent ctc-lacZ activity (P
0.05;GLMwithpost-hocTukey’sHSDtest)tolevelsequivalent
to those in a sigB strain (Fig. 3) (P  0.05) without reducing
-galactosidase activity from a A-dependent lacZ fusion (30)
(Fig. 3), further supporting FPSS speciﬁcity for inhibiting B ac-
tivity.
DISCUSSION
Byusingahigh-throughputscreenofapproximately57,000small
molecules, 41 candidate compounds were identiﬁed as potential
inhibitors of L. monocytogenes B activity. Through subsequent
screens, we identiﬁed a compound designated FPSS that speciﬁ-
callyinhibitsB-mediatedtranscription,asshownbyqRT-PCRof
B-dependent genes and whole-genome microarray analysis of
cells treated with the compound. This compound also signiﬁ-
cantly reduces L. monocytogenes invasion into human intestinal
epithelial cells and inhibits B-directed activity in the Gram-
positive bacterium B. subtilis, indicating that this compound in-
hibits B-mediated transcription across genera. Overall, our data
showthatFPSS(i)inhibitsexpressionoftheBregulonwithhigh
speciﬁcity,yieldingtranscriptionalproﬁlessimilartothosegener-
ated by a genetic null mutation of the sigB gene, and (ii) speciﬁ-
callyinhibitsexpressionofB-dependentgenesimportantforvir-
ulence, stress response, and other functions associated with
L.monocytogenessurvivalandgrowthinthegastrointestinaltract.
In combination with previous reports that identiﬁed small mole-
culesthatinterferewithvirulencefactorsandvirulenceactivation
and that show therapeutic promise (14, 31), our results suggest
that, in addition to its role as a promising tool for studying regu-
latory networks involving B, FPSS also may represent a com-
pound that can be developed into a therapeutic agent.
FIG 3 B. subtilis -galactosidase assay. (A) -Galactosidase activity of a B. subtilis strain with a B-dependent Pctc-lacZ reporter fusion treated with (i) 0.3 M
NaCl and DMSO, (ii) 0.3 M NaCl and 64 M FPSS, and (iii) 0.3 M NaCl and 8 M FPSS; this panel also shows the activity for an isogenic sigB strain with the
Pctc-lacZ reporter fusion treated with 0.3 M NaCl and DMSO. (B) -Galactosidase activity of a B. subtilis strain with a A-dependent PrsbRSTU-lacZ fusion
treated with either (i) 0.3 M NaCl and 64 M FPSS or (ii) 0.3 M NaCl and DMSO. The data are means from at least three biological replicates; error bars show
the standard deviations. Different letters above the bars indicate strains or treatments that differed signiﬁcantly (P  0.05; GLM Tukey).
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lence, stress response, and other functions that are associated
withL.monocytogenesgrowthandsurvivalinthegastrointesti-
nal tract. B is well recognized as an important transcriptional
regulator in multiple Gram-positive genera. For example, B reg-
ulates transcription of genes contributing to stress response, vir-
ulence,orbothinlow-GCGram-positivemicrobes,includinghu-
man pathogens such as Bacillus cereus (32, 33), Bacillus anthracis
(34),Staphylococcusaureus(35,36),andtheopportunisticpatho-
gen S. epidermidis (37). B activates transcription of a large num-
ber of target genes across the genera and species reported to date
(e.g., L. monocytogenes, Listeria innocua, S. aureus, and B. subtilis)
(8, 38, 39). FPSS treatment of L. monocytogenes affects expression
of B-dependent genes that are upregulated in the host intestine
butthathadnotbeenidentiﬁedpreviouslyasBdependentunder
other in vitro conditions. Speciﬁcally, among 172 genes in
L. monocytogenes EGD-e that were upregulated by B in the mu-
rineintestinallumen(6),FPSStreatmentsigniﬁcantlydownregu-
lated 126 genes; 17 genes downregulated by FPSS had been iden-
tiﬁed as B dependent only in the intestinal lumen (6) but not in
other in vitro test systems. Thus, identiﬁcation of B-dependent
genes in L. monocytogenes treated with FPSS may provide new
insight into B-dependent gene regulation that may be critical
during the gastrointestinal stage of infection. For example, the
PrfA regulon was signiﬁcantly enriched among genes downregu-
lated by FPSS treatment, including two PrfA-dependent genes
(i.e., lmo0937 and plcA) that had not been identiﬁed previously as
B regulated. These ﬁndings are consistent with B’s role, via the
P2prfA promoter, in directly upregulating prfA transcription (11–
13) and also support the idea that B-dependent upregulation of
prfA transcription plays a critical role during intestinal stages of
infection. Activation of B in the intestinal lumen thus appears to
increase expression of B-dependent inlA, which is required for
intestinal epithelial cell invasion (40), and also primes expression
of PrfA, which is critical for regulating virulence gene expression
during the subsequent intracellular stages of infection.
FPSS-treatedL.monocytogenesalsohadhighertranscriptlevels
than nontreated cells for a number of genes involved in che-
motaxis and motility. Several genes in a large operon encoding
ﬂagellar structural components were previously reported to be
negatively regulated by B (8), and sigB-null mutants also exhib-
ited increased swarming (6, 8). B-dependent downregulation of
transcriptsencodingﬂagellarcomponentsandoverallmotilityap-
peartobeatleastpartiallyduetoB-dependenttranscriptionofa
long untranslated region (UTR) upstream of mogR, which en-
codes a negative regulator of L. monocytogenes motility. Reduced
transcription of this UTR not only reduces mogR transcript levels
(thereby increasing ﬂagellar motility) but also appears to increase
transcript levels for some ﬂagellar genes, as the B-dependent
UTR also decreases ﬂagellin gene transcripts through an
antisense-RNA-type mechanism (6, 8). While L. monocytogenes
ﬂagellarmotilityappearstocontributetointestinalinvasion(41),
B-dependentdownregulationofﬂagellarexpressionintheintes-
tinal lumen may be critical for subsequent stages of infection, as
Listeria downregulates ﬂagellar gene expression during infection
(10)toevadetheimmunesystem;increasedexpressionofﬂagellar
components can induce potent proinﬂammatory effects via
TLR5-mediated immunogenicity (42).
Inhibitorsofalternativefactoractivationrepresentpoten-
tialavenuesfordevelopmentintotherapeutics.Inadditiontoits
value as a compound that can be used to study regulatory path-
ways involving B, FPSS also may provide a starting point for
development of new therapeutic compounds that interfere with
regulatory pathways critical for infection and virulence. Several
small molecules that target transcription regulators inhibit viru-
lence and virulence-associated characteristics in vitro and in vivo,
suggestingthatthesetargetsaresuitablefordevelopmentofnovel
therapeutics against bacterial infections (43, 44). Importantly,
prokaryotic transcriptional machinery, as represented by interac-
tions between 70 and the = subunit of core RNA polymerase in
Escherichia coli, can be disrupted by small molecules without af-
fecting eukaryotic transcription (45). Consequently, the thera-
peuticpotentialofnovelcompoundsthatinterferewithtranscrip-
tional regulation of bacterial virulence functions is of emerging
interest.
Virstatin is an example of a small molecule with therapeutic
potentialthathasbeenshowntoinhibittranscriptionalregulation
in V. cholerae. Virstatin interferes with the virulence gene regula-
tor ToxT, a member of the AraC family of transcriptional regula-
tors, thus showing potential for treatment of Vibrio infections
(14).Small-moleculeinhibitorsalsohavebeenidentiﬁedforother
membersoftheAraCtranscriptionfactorfamily,e.g.,MarA,SoxS
and Rob in E. coli (43) and LcrF in Yersinia spp. (44). As with B,
AraC-typeregulatorstypicallycontributetotranscriptionofmul-
tiple stress response (46) and virulence factors (47, 48); therefore,
inhibition of these and similar transcriptional regulators can re-
sultinbroadphysiologicalconsequencesfortheaffectedmicrobes
(43).
Thesmallmoleculeidentiﬁedhere,FPSS,inhibitsBactivityat
an IC50 o f3t o3 . 5M. By comparison, the ToxT inhibitor virsta-
tin (14) has an MIC between 3 and 40 M, depending on the
target strain. Minimal bactericidal concentrations of gentamicin,
ampicillin,andstreptomycinagainstL.monocytogenesrangefrom
2t o4 6M (49). In addition to its promising IC50 prior to struc-
tural optimization, FPSS produces highly speciﬁc, genome-wide
reduction of B-directed activity, including inhibited expression
ofB-dependentvirulencegenessuchasinlAB,bsh,bilE,clpC,and
hfq (5–8, 16, 17). Furthermore, opuC (50) and gadA (51), which
are important for gastrointestinal survival in the host, are also
signiﬁcantly downregulated by FPSS. FPSS clearly inhibits tran-
scription of a number of genes with functions in virulence and
infection, thus increasing its therapeutic potential over com-
pounds that target only one virulence factor (43). The contribu-
tions of B to L. monocytogenes virulence are also supported by
phenotypic evidence, including reduced virulence of a sigB
straininaguineapigmodelofinfection(9)andreducedinvasion
ofhumanCaco-2cellsbyasigBstrain(9,40),consistentwiththe
reduced invasiveness for FPSS-treated L. monocytogenes observed
here. Importantly, B also contributes to establishment of infec-
tion and virulence in other Gram-positive pathogens, including
B. anthracis and S. aureus.AB. anthracis sigB mutant is less viru-
lent than the parent strain, producing a 1-log reduction in 50%
lethaldose,perhapsbecauseBenhancestheabilityofB.anthracis
to persist in the bloodstream of a mammalian host (34). In S. au-
reus, B directly and indirectly modulates global regulatory ele-
ments involved in virulence functions (52). Functional loss of B
resultsindecreasedS.aureusvirulenceincentralvenouscatheter-
related diseases manifested by signiﬁcantly reduced multiorgan
infection (53). Similar to B. anthracis, B is suggested to promote
S. aureus survival in the bloodstream, preventing clearance and
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and optimization of FPSS thus may provide an opportunity to
develop novel therapeutics for some important Gram-positive
pathogens.
MATERIALS AND METHODS
Strain and media selection. Strains used in this study included the
L. monocytogenes parent strain 10403S (serotype 1/2a) (55), its otherwise
isogenic sigB derivative (FSL A1-254) (56), a reporter strain for B ac-
tivity (FSL S1-063 [10403S opuCA-gus]) (7, 57, 58), and a negative-
control reporter strain for B activity (FSL S1-059 [sigB opuCA-gus])
(Table S5). To evaluate the effectiveness of a selected small molecule to
inhibit B activity in a Gram-positive genus other than Listeria, B. subtilis
strains bearing reporter fusions for either B or A activity and a sigB
negative-control reporter strain (Table S5) were also tested. To achieve
lowbackgroundﬂuorescence,achemicallydeﬁnedminimalmedium(59)
with 25 mM glucose (DMG) (60) was used for the high-throughput
screen. Cells were grown in brain heart infusion broth (BHI; Difco,
Sparks, MD) for phenotypic and transcriptional proﬁling assays.
Primary high-throughput cell-based small-molecule screen. The
L. monocytogenes opuCA-gus fusion strain FSL S1-063 was used in a cell-
based high-throughput screen (HTS) against ~57,000 compounds. As
reported at http://ChemBank.Broad.Harvard.edu, the libraries included
the following: (i) known bioactive compounds, including FDA-approved
drugs (i.e., the SPBio and SMP libraries); (ii) synthetic compounds from
diversity-orientedsynthesis(e.g.,theCMLD,ICCB,PK04,Ald1.1-H,and
Sulf1.1-A libraries); (iii) natural products (i.e., the PhilEx and ICBGEx
libraries); and (iv) commercially available compounds (e. g., the Chem-
Div3, Maybridge4, and TimTec1 libraries). Table S1 contains a complete
listing of libraries screened for this study.
Multidropliquid-handlingrobots(Matrix,ThermoFisher)wereused
to dispense 27 l of DMG into black-walled clear-bottom 384-well plates
(Nunc,Rochester,NY),andthen100nlofeachsmall-moleculestockwas
transferredfromthelibrarystockorsourceplatetotheassayplateswitha
CyBi-WellVariopipettor(CyBioAG,Jena,Germany).Finalexperimental
concentrations of the small molecules used in the assays were dependent
on each stock concentration [e.g., (E)-N,2-diphenylethenesulfonamide
had a stock concentration of 19.3 mM, producing a 64.3 M ﬁnal con-
centration in each well]. Each source plate contained approximately 15
wells to which only dimethyl sulfoxide (DMSO) was added, as the small
molecules were dissolved in DMSO; these wells are referred to as DMSO-
only negative-internal-control wells. All source plates were prepared in
duplicate to provide experimental replicates (i.e., plates A and B). Two
plates in which all wells contained medium with DMSO and L. monocy-
togenes(inoculatedasdetailedbelow)wereincludedasexternalplatecon-
trols.L.monocytogenesstrainsweregrowntoanopticaldensityat600nm
(OD600)ofapproximately0.4(3hours)inBHI,cultureswerediluted1:50
with DMG, and then 3 l of the appropriate diluted culture was added to
each well. As a control, a custom assay plate containing 192 wells of the
10403S opuCA-gus strain FSL S1-063 and 192 wells of the otherwise iso-
genic sigB opuCA-gus strain FSL S1-059 was treated with only DMSO.
All plates were sealed and incubated for 18 h at 37°C. To determine
bacterial growth or inhibition in the presence of the compounds, absor-
bance (OD600) was measured using a Synergy HT multimode microplate
reader (Biotek Instruments, Winooski, VT) after ~18 h of incubation. To
measure ﬂuorescence for -glucuronidase (GUS) activity determination,
black seals (PerkinElmer, Waltham, MA) were afﬁxed to the bottoms of
the plates after the absorbance readings were completed. Cells were then
lysed using 5 lo f2  CelLyticB (Sigma, St. Louis, MO) and a protease
inhibitor cocktail mixture (1 ml 2 CelLyticB and 0.05 ml protease in-
hibitor cocktail; Sigma), immediately prior to the addition of 4 lo f
1.6 mg/ml 4-methylumbelliferyl -D-glucuronide hydrate (4-MUG;
Sigma)inDMSO.Reactionmixtureswereincubatedinthedarkfor1hat
roomtemperature(~23°C),andreactionswerestoppedbytheadditionof
0.2MNa 2CO3.FluorescencewasreadusingaWallac2102EnVisionMul-
tilabelReader(PerkinElmer)withanexcitationwavelengthof355nmand
an emission of 460 nm.
Statistical analysis of primary screen data. To identify compounds
that inhibited B activity without affecting L. monocytogenes growth,
opuCA-directed GUS activity in the presence of each compound was cal-
culated by dividing relative ﬂuorescence units (RFU) by cell density in
OD600 units (RFU/OD) (61). Statistical analyses were conducted in col-
laborationwiththeBroadInstituteandperformedaspreviouslydescribed
(62, 63). Raw and analyzed data were deposited in ChemBank (64, 65).
The software package Spotﬁre DecisionSite Analytics (TIBCO Spotﬁre,
Somerville, MA) was used for two-dimensional data visualization.
Secondary screen and dose response curve. Forty-one compounds
that appeared to inhibit B activity (Z score of -3 in both replicates)
were selected for secondary cell-based screening using the assay and re-
porter fusion described above to calculate initial IC50s. Each compound
was diluted in DMSO in a series of six 1/5 dilutions of the initial stock
concentration [e.g., starting from 19.3 mM stock, (E)-N,2-
diphenylethenesulfonamide was diluted in a series of six 1 to 5 dilutions,
yielding concentrations of 3.86 mM to 1.24 M]. The small molecules at
these concentrations were then dispensedinto the assay plates.
Small-molecule microarray screens. Two different arrays, each
printed with 8,500 small-molecule (SM) spots and 1,500 DMSO control
spots,wereusedtoscreenforbindingofBtothesmallmolecules.Small-
molecule microarrays (SMMs) were printed on glass slides at the Broad
Instituteasdescribedpreviously(66–68).TheimmobilizedSMsincluded
8,500 compounds created by diversity-oriented synthesis and 8,500 com-
pounds representing natural products, FDA-approved drug-like com-
pounds, commercial compounds, and known bioactive compounds (Ta-
ble S1) (68; http://Chembank.broadinstitute.org). SMM screening (three
replicates) was performed as described by Bradner et al. (66). His-tagged
BwaspuriﬁedfromE.coliM15,kindlyprovidedbyW.Goebel(69).Data
analysesincluded(i)assessmentofsignal-to-noiseratio(SNR)ofthespot
feature; (ii) Z score calculations based on comparison of signals from
compound spots to signals from DMSO control spots within a slide; and
(iii) composite Z score calculations for data from the three replicates.
SpotﬁreAnalyticssoftwarewasusedforthree-dimensionaldatavisualiza-
tion.
FPSS. (E)-N,2-diphenylethenesulfonamide, the compound identiﬁed
by HTS as being responsible for the greatest inhibition of B activity, was
notcommerciallyavailable.Therefore,theanalogﬂuoro-phenyl-styrene-
sulfonamide [IUPAC name (E)-N-(4-ﬂuorophenyl)-2-phenylethenesul-
fonamide;ChemBankID,2063822;MW277.3]wasobtainedfromEnam-
ineLtd.(Kiev,Ukraine).FPSSwasdissolvedinDMSOtoaconcentration
of 10 mM. The solution was ﬁlter sterilized using with a 0.1-m ﬁlter
(Omniporemembraneﬁlter;MilliporeCorporation,Billerica,MA)anda
Swinney stainless 13-mm holder for syringe ﬁltration (Millipore Corpo-
ration).
Bile salt hydrolase (BSH) activity assay. As L. monocytogenes bsh,
which encodes bile salt hydrolase, is B dependent (5, 7, 15), a qualitative
BSH activity assay was used to determine the FPSS concentration needed
for B inhibition. Four-well multidish plates (26 mm by 33 mm; Nunc)
containing 6 ml of either BHI agar or de Man, Rogosa and Sharp (MRS)
agar medium (BD Biosciences, San Jose, CA) containing 0.5% (wt/vol)
glycodeoxycholicacidsodium(GDCA)salt(Calbiochem,SanDiego,CA)
(70)witheithernoFPSSor96,193,or290MofFPSS[1.5,3,or4.5times
the64.3Mconcentrationusedfor(E)-N,2-diphenylethenesulfonamide
intheHTS]werepreparedandallowedtodryovernight.L.monocytogenes
10403SandsigBweregrowninBHIbrothtoexponentialphase,deﬁned
asanOD600of0.4,andthen4lofculturewasspottedinparallelonMRS
and BHI agars. The MRS agar plates were incubated anaerobically using
theBD-BBLGasPakanaerobicsystem(BectonDickinson,FranklinLakes,
NJ), while BHI plates were incubated aerobically. Both sets of plates were
incubatedfor48hat37°Candthenwerevisuallyassessedforgrowth(BHI
plates) or the presence of a white precipitate comprised of deconjugated
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three times.
RNAisolation.ForRNAisolation,L.monocytogenes10403SandsigB
strains were initially grown overnight in 5 ml of BHI broth at 37°C with
shaking(230rpm),followedbysubculturingtwice,eachtimeatanOD600
of 0.4, using a 1% (vol/vol) transfer into 5 ml of prewarmed BHI. When
the second subculture reached an OD600 of 0.4, cells were treated with a
totalvolumeof76lcomprisingFPSS(toyieldﬁnalconcentrationsrang-
ing from 1 Mt o1 2 8M) and/or DMSO, followed immediately by
addition of 324 l of either 5 M NaCl (to yield a ﬁnal concentration of
0.3 M NaCl, an osmotic stress that induces B activity [8]) or (ii) sterile
distilledwater.Treatedcultureswerethenincubatedat37°Cwithshaking
(230 rpm) for 10 min, followed by addition of 2 volumes of RNAprotect
(Qiagen Inc., Valencia, CA) and subsequent incubation at room temper-
ature for 10 min. The cells were harvested following centrifugation for
10 min at 5,000  g, and cell pellets were stored at 80°C until RNA was
extracted and DNase treated using an Ambion RiboPure kit (Ambion,
Austin, TX) according to the manufacturer’s instructions. RNA concen-
trations and purity were assessed using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Rockland, DE). RNA quality was
analyzed using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA),andonlyRNAwithanintegritynumberof8wasused.Eachtreat-
ment was performed 3 times.
TaqMan qRT-PCR. Transcript levels for the B-dependent genes
opuCA and gadA and the housekeeping genes rpoB and gap were quanti-
ﬁedwithTaqManprimersandprobes(13,58,71)usingRNApreparedas
described above and an ABI Prism 7000 sequence detection system (Ap-
pliedBiosystems,FosterCity,CA)aspreviouslydescribed(71).qRT-PCR
was also used to determine the FPSS IC50. Inhibition was measured using
opuCA transcript levels determined with RNA isolated from cells treated
with a series of 1:2 dilutions of FPSS, with concentrations ranging from
128 to 1 M. These data were assessed using SigmaPlot 10.0 (SYSTAT
Software Inc., Evanston, IL) standard curve analysis under the pharma-
cology function.
Whole-genome microarray. cDNA labeling for microarray analyses
andmicroarrayhybridizationwereperformedaspreviouslydescribed(5)
using L. monocytogenes whole-genome microarrays (8, 72). Raw intensity
values for all probes on each array were normalized using pin-tip LOW-
ESS (8) in R version 2.2.1 with the LIMMA package. Signals from two
replicate probes on each array were then averaged and log2 transformed.
Differences in transcript levels between strains were determined using a
linear model, and P values were determined using eBayes. Differences in
transcript levels were considered meaningful if they met the following
three criteria: (i) adjusted P values of 0.05 (ii) absolute fold changes of
2and(iii)aprobecross-hybridizationindex(CHI)of90%.Onegene
(i.e., lmo0263) fulﬁlled criteria (i) and (ii) but not (iii) (probe CHI was
80%) and therefore was not included in our analyses.
Gene set enrichment analysis (GSEA; Broad Institute, Cambridge,
MA) (73) was used to identify gene sets that were signiﬁcantly enriched
among up- or downregulated genes. GSEA was run on the ranked list of
log fold change values obtained from the ﬁtted normalized data in
LIMMA with 1,000 permutations and exclusion of gene sets with 5o r
2,000members.GeneswereclassiﬁedintosetsbasedontheTIGRCom-
prehensive Microbial Resource (http://cmr.tigr.org) subrole categories
for L. monocytogenes EGD-e. False discovery rate q values of 0.25 were
considered signiﬁcant (73).
Caco-2 invasion assay. L. monocytogenes invasion assays using the
human colorectal adenocarcinoma epithelial cell line Caco-2 (ATCC
HTB-37) were performed as described by Garner et al. (9). L. monocyto-
genes 10403S and sigB strains were initially grown overnight in 5 ml of
BHI broth at 37°C with shaking (230 rpm), then were subcultured twice,
at an OD600 of 0.4, using a 1% (vol/vol) transfer into 5 ml of prewarmed
BHI. When the second subculture reached an OD600 of 0.4, cells were
treated with (i) FPSS to yield ﬁnal concentrations of 64 Mo r8M
(lowest concentration with full efﬁcacy according to qRT-PCR) or (ii)
DMSO as well as NaCl (0.3 M ﬁnal concentration) as described above,
except that treated cultures were incubated at 37°C for 30 min. For infec-
tion, the Caco-2 cells were inoculated with approximately 2  107
L.monocytogenesorganisms;bacterialnumberswereconﬁrmedbyplating
on BHI agar. Four biological replicates were each performed in triplicate
wells. Statistical analysis was performed using one-way analysis of vari-
ance (ANOVA) and Tukey’s studentized range (honestly signiﬁcant dif-
ference [HSD]) test, performed in SAS 9.0 (SAS Institute).
-GalactosidaseenzymeassaysinB.subtilis.B.subtilisstrainPB198
(amyE::pDH32-ctc trpC2 [74]) and the otherwise isogenic sigB strain
PB345 (amyE::pDH32-ctc sigB3::spc trpC2 [75]) were used as reporter
strains for measuring B activity (Table S5). Effects of FPSS on the A
housekeeping sigma factor in B. subtilis were tested using B. subtilis strain
PB252 (amyE::PA-lacZ trpC2 [30]). Strains were grown overnight in 5 ml
of buffered Luria-Bertani (LB) broth at 37°C with shaking (230 rpm) and
then were subcultured twice, at an OD600 of 0.4, using a 1% (vol/vol)
transferinto5mlofprewarmedLB.Whenthesecondsubculturereached
OD600of0.4,cellsweretreatedwith(i)FPSS(8or64M)orDMSOonly
(as a control) and (ii) DMSO as well as NaCl (0.3 M ﬁnal concentration)
as described above, with treated cultures being incubated at 37°C for
30 min. After this incubation, the OD600 was recorded, and 0.2 ml of the
culture was added to a tube containing 2.8 ml Z buffer, followed by the
addition of 20 l toluene to permeabilize the cells. A prewarmed 0.4-ml
volume of 4-mg/ml ortho-nitrophenyl--galactoside (ONPG) was
added, and the time of addition was noted. After 85 min, 1 ml of 1 M
sodiumcarbonatewasaddedtostopthereaction,andtheOD420wasread.
Millerunitswerecalculatedaspreviouslydescribed(76).-Galactosidase
activityresultswereanalyzedusingone-wayANOVAandTukey’sstuden-
tized range (HSD) test.
Microarray data accession number. Data from microarray experi-
mentsweresubmittedtotheGeneExpressionOmnibus(GEO)database,
assigned accession number GSE16887, and approved.
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